SCHEMBL7147744

SCHEMBL7147744

COc1ccc(COc2ccc(OCc3ccc(OC)cc3)c(C=O)c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 1/20 0.66
RAB9A P51151 5/20 0.61
NPC1 O15118 4/20 0.61
TDP1 Q9NUW8 1/20 0.61
SMN1; SMN2 Q16637 2/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
APP P05067 5/20 0.49
CCR5 P51681 1/20 0.48
KDM4E B2RXH2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
MEN1 O00255 1/20 0.48
CASP3 P42574 1/20 0.48
KMT2A Q03164 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21347524 0.95 TUBB1 (0.59) TUBB1RAB9ANPC1TDP1SMN1; SMN2
SCHEMBL28611584 0.94 TUBB1 (0.74) TUBB1RAB9ANPC1TDP1SMN1; SMN2
SCHEMBL22090540 0.92 TUBB1 (0.56) TUBB1RAB9ANPC1TDP1SMN1; SMN2
SCHEMBL30660124 0.92 TUBB1 (0.56) TUBB1RAB9ANPC1TDP1SMN1; SMN2
SCHEMBL5286017 0.88 ALDH1A1 (0.56) TUBB1RAB9ANPC1TDP1SMN1; SMN2
SCHEMBL21370452 0.88 NPC1 (0.61) TUBB1RAB9ANPC1TDP1SMN1; SMN2
SCHEMBL7146795 0.88 MAOB (0.58) TUBB1RAB9ANPC1TDP1SMN1; SMN2
SCHEMBL29859226 0.87 CCR5 (0.63) TUBB1RAB9ANPC1TDP1SMN1; SMN2
SCHEMBL5631282 0.87 TUBB1 (0.51) TUBB1RAB9ANPC1TDP1SMN1; SMN2
SCHEMBL30873551 0.87 MAOB (0.55) TUBB1RAB9ANPC1TDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US disclosed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US disclosed
EP-1189894-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-03-27 EP disclosed
WO-2001057006-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037901-A1 Thiazolidinecarboxyl acids TPMT, NAT1, THRA TUBB1 267/4885RAB9A 4021/4885NPC1 1475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.